• linkedin
  • Increase Font
  • Sharebar

    Metformin/statin combo therapy reduces PCa mortality

    Treatment with metformin plus a statin or with a statin alone significantly reduces overall and disease-specific mortality in men with high-risk prostate cancer, according to the findings of a population-based study presented at the American Society of Clinical Oncology annual meeting in Chicago.  

    Related: Statins delay PCa progression in patients on ADT

    Using Surveillance, Epidemiology, and End Results-Medicare linked data, the study identified almost 21,000 men diagnosed with high-risk prostate cancer between 2007 and 2009. Based on follow-up through Dec. 31, 2011, hazard ratios for mortality outcomes associated with use of metformin and/or a statin were calculated in a Cox regression analysis adjusting for numerous sociodemographic, clinical, and prostate cancer-related variables.

    Statin plus metformin vs. statin alone

    Compared to the reference group of men on neither agent, men on a statin plus metformin had significant reductions in both overall mortality (34%) and prostate cancer-specific mortality (PCSM; 43%). Use of a statin alone was associated with slightly lower reductions in overall mortality (25%) and PCSM (40%), but the benefits were still statistically significant.

    Findings from a sensitivity analysis focusing on patients with a comorbidity score of 0 or 1 showed similar significant reductions in overall mortality and PCSM among men using the combination regimen or a statin alone. Use of metformin alone, however, had no significant benefit in reducing overall mortality or PCSM in the overall population or in the subgroup with minimal comorbidities, reported first author Grace L. Lu-Yao, PhD, of Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick. 

    NEXT: Findings consistent with preclinical results

    More on Prostate Cancer

    Statins may improve prostate cancer outcomes

    Upfront chemo called ‘standard’ in hormone-naïve PCa

    Oral antiandrogen safe, well tolerated in phase II trial

    Cheryl Guttman Krader
    Cheryl Guttman Krader is a contributor to Dermatology Times, Ophthalmology Times, and Urology Times.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results